• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Rivaroxaban Versus Apixaban: A Comparison Without a Simple Solution.

作者信息

Cohen Marc, Spyropoulos Alex C, Goodman Shaun G, Spinler Sarah A, Bonaca Marc P, Redling Theresa M, Visveswaran Gautam, Sohal Sumit

机构信息

Department of Medicine, Newark Beth Israel Medical Center, Newark, NJ.

Department of Medicine, Rutgers-New Jersey Medical School, Newark, NJ.

出版信息

Mayo Clin Proc Innov Qual Outcomes. 2024 Jun 11;8(4):321-328. doi: 10.1016/j.mayocpiqo.2024.05.004. eCollection 2024 Aug.

DOI:10.1016/j.mayocpiqo.2024.05.004
PMID:38974528
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11223068/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3285/11223068/e867070d29f7/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3285/11223068/354eb2b088f9/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3285/11223068/191bc8fc3faa/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3285/11223068/e867070d29f7/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3285/11223068/354eb2b088f9/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3285/11223068/191bc8fc3faa/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3285/11223068/e867070d29f7/gr3.jpg

相似文献

1
Rivaroxaban Versus Apixaban: A Comparison Without a Simple Solution.利伐沙班与阿哌沙班对比：无简单答案的比较
Mayo Clin Proc Innov Qual Outcomes. 2024 Jun 11;8(4):321-328. doi: 10.1016/j.mayocpiqo.2024.05.004. eCollection 2024 Aug.
2
An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.达比加群、利伐沙班和阿哌沙班治疗心房颤动的间接比较。
Thromb Haemost. 2012 Sep;108(3):476-84. doi: 10.1160/TH12-02-0093. Epub 2012 Jun 28.
3
Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.新型口服抗凝药物在预防心房颤动卒中方面的疗效和安全性的间接比较。
J Am Coll Cardiol. 2012 Aug 21;60(8):738-46. doi: 10.1016/j.jacc.2012.03.019. Epub 2012 May 9.
4
Comparison of Adherence to Rivaroxaban Versus Apixaban Among Patients With Atrial Fibrillation.心房颤动患者中利伐沙班与阿哌沙班依从性的比较。
Clin Ther. 2016 Nov;38(11):2477-2488. doi: 10.1016/j.clinthera.2016.09.014. Epub 2016 Oct 24.
5
Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation.达比加群、利伐沙班和阿哌沙班与华法林相比治疗非瓣膜性心房颤动的有效性和安全性。
J Am Heart Assoc. 2016 Jun 13;5(6):e003725. doi: 10.1161/JAHA.116.003725.
6
Real-world evidence of stroke prevention in patients with nonvalvular atrial fibrillation in the United States: the REVISIT-US study.美国非瓣膜性心房颤动患者卒中预防的真实世界证据：REVISIT-US研究
Curr Med Res Opin. 2016 Dec;32(12):2047-2053. doi: 10.1080/03007995.2016.1237937. Epub 2016 Sep 20.
7
Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis.新型口服抗凝药物在预防心房颤动卒中中的一级和二级预防：间接比较分析。
BMJ. 2012 Nov 5;345:e7097. doi: 10.1136/bmj.e7097.
8
A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban.阿哌沙班与利伐沙班药代动力学和药效学的随机直接比较。
Clin Pharmacol. 2014 Nov 13;6:179-87. doi: 10.2147/CPAA.S61131. eCollection 2014.
9
Evaluation of rivaroxaban-, apixaban- and dabigatran-associated hemorrhagic events using the FDA-Adverse event reporting system (FAERS) database.使用 FDA 不良事件报告系统 (FAERS) 数据库评估利伐沙班、阿哌沙班和达比加群相关出血事件。
Int J Clin Pharm. 2021 Dec;43(6):1508-1515. doi: 10.1007/s11096-021-01273-8. Epub 2021 Jun 9.
10
Meta-Analysis Comparing Apixaban Versus Rivaroxaban for Management of Patients With Nonvalvular Atrial Fibrillation.比较阿哌沙班与利伐沙班治疗非瓣膜性心房颤动患者的Meta分析
Am J Cardiol. 2022 Mar 1;166:58-64. doi: 10.1016/j.amjcard.2021.11.021. Epub 2021 Dec 20.

引用本文的文献

1
Comparative Effectiveness and Safety of Direct Oral Anticoagulants Versus Vitamin K Antagonists in Elderly Patients With Atrial Fibrillation: A Systematic Review.直接口服抗凝剂与维生素K拮抗剂在老年房颤患者中的比较有效性和安全性：一项系统评价
Cureus. 2025 Jun 9;17(6):e85615. doi: 10.7759/cureus.85615. eCollection 2025 Jun.

本文引用的文献

1
Efficacy and safety of rivaroxaban versus apixaban for venous thromboembolism: A systematic review and meta-analysis of observational studies.利伐沙班与阿哌沙班治疗静脉血栓栓塞症的疗效和安全性：观察性研究的系统评价和荟萃分析
J Thromb Thrombolysis. 2024 Mar;57(3):453-465. doi: 10.1007/s11239-023-02926-3. Epub 2023 Dec 21.
2
Rivaroxaban versus Apixaban for Treatment of Cancer-Associated Venous Thromboembolism in Patients at Lower Risk of Bleeding.利伐沙班与阿哌沙班治疗出血风险较低患者的癌症相关性静脉血栓栓塞症对比研究
TH Open. 2023 Jul 10;7(3):e206-e216. doi: 10.1055/s-0043-1770783. eCollection 2023 Jul.
3
American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults.
美国老年医学学会 2023 年更新了老年人潜在不适当药物使用的 AGS Beers 标准®。
J Am Geriatr Soc. 2023 Jul;71(7):2052-2081. doi: 10.1111/jgs.18372. Epub 2023 May 4.
4
Long-term comparative effectiveness and safety of dabigatran, rivaroxaban, apixaban and edoxaban in patients with atrial fibrillation: A nationwide cohort study.达比加群、利伐沙班、阿哌沙班和依度沙班用于房颤患者的长期比较疗效和安全性：一项全国性队列研究。
Front Pharmacol. 2023 Feb 2;14:1125576. doi: 10.3389/fphar.2023.1125576. eCollection 2023.
5
Effectiveness and Safety of Direct Oral Anticoagulants Among Patients with Non-valvular Atrial Fibrillation and Multimorbidity.非瓣膜性心房颤动合并多种疾病患者中直接口服抗凝剂的有效性和安全性。
Adv Ther. 2023 Mar;40(3):887-902. doi: 10.1007/s12325-022-02387-9. Epub 2022 Dec 17.
6
Delaying clinical events among patients with non-valvular atrial fibrillation treated with oral anticoagulants: Insights from the ARISTOPHANES study.在口服抗凝剂治疗的非瓣膜性心房颤动患者中延迟临床事件：来自 ARISTOPHANES 研究的见解。
Eur J Intern Med. 2023 Feb;108:37-42. doi: 10.1016/j.ejim.2022.10.021. Epub 2022 Nov 28.
7
Head-to-head efficacy and safety of rivaroxaban, apixaban, and dabigatran in an observational nationwide targeted trial.在一项全国性观察性靶向试验中，利伐沙班、阿哌沙班和达比加群的头对头疗效及安全性
Eur Heart J Cardiovasc Pharmacother. 2022 Dec 15;9(1):26-37. doi: 10.1093/ehjcvp/pvac063.
8
Comparative Effectiveness and Safety Between Apixaban, Dabigatran, Edoxaban, and Rivaroxaban Among Patients With Atrial Fibrillation : A Multinational Population-Based Cohort Study.阿哌沙班、达比加群、依度沙班和利伐沙班在房颤患者中的疗效和安全性比较：一项基于多国人群的队列研究。
Ann Intern Med. 2022 Nov;175(11):1515-1524. doi: 10.7326/M22-0511. Epub 2022 Nov 1.
9
Using primary care data to assess comparative effectiveness and safety of apixaban and rivaroxaban in patients with nonvalvular atrial fibrillation in the UK: an observational cohort study.利用初级保健数据评估 UK 非瓣膜性心房颤动患者中阿哌沙班和利伐沙班的疗效和安全性：一项观察性队列研究。
BMJ Open. 2022 Oct 17;12(10):e064662. doi: 10.1136/bmjopen-2022-064662.
10
Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants: A Review.剂量降低的直接口服抗凝剂的疗效和安全性考虑：综述。
JAMA Cardiol. 2022 Jul 1;7(7):747-759. doi: 10.1001/jamacardio.2022.1292.